

# NeuroNet Data Room

## Executive Summary

- Founded: 2020
- Location: Boston, MA, USA
- Team: 42 employees (18 PhDs in Neuroscience and AI)
- Key Product: SynapseAI™ Platform

## Financial Overview

- Current Fundraise: \$7M Seed Round
- Share Price: \$75/unit
- Minimum Investment: \$15,000
- Revenue (2023): \$1.2M
- Projected Revenue (2024): \$4.5M
- Burn Rate: \$380,000/month
- Previous Funding: \$3M Pre-seed

## Technology

- Proprietary AI-powered neural activity simulation platform
- Advanced biomarker detection algorithms
- Brain-computer interface development
- 8 patents filed (3 granted, 5 pending)
- SynapseAI™ platform validated by 3 major research institutions

## Market Analysis

- Global Neuroscience Market: \$38B (2023)
- Projected Market Size: \$85B by 2030
- Target Segments:
  - Research Institutions
  - Pharmaceutical Companies
  - Healthcare Providers
  - Assistive Technology Market

## Clinical Partnerships

- 5 Leading Research Hospitals
- 3 Major Academic Institutions
- 2 Pharmaceutical Companies

- **Current Clinical Trials: 3 active**

## **Use of Funds**

- **R&D Enhancement: 40%**
- **Clinical Trials: 25%**
- **Platform Development: 20%**
- **Team Expansion: 10%**
- **Operations: 5%**

## **Achievements & Milestones**

- **Successful identification of novel Alzheimer's biomarkers**
- **Validation study with 92% accuracy in early-stage Parkinson's detection**
- **FDA Pre-submission meeting completed**
- **ISO 13485 certification in progress**

## **Risk Factors**

- **Regulatory approval timelines**
- **Competition from established medical technology companies**
- **AI model validation requirements**
- **Clinical trial outcomes**
- **Intellectual property protection**
- **Healthcare industry adoption rate**

## **Competitive Advantages**

- **First-mover in AI-powered neural simulation**
- **Proprietary biomarker detection algorithms**
- **Strong IP portfolio**
- **Established research partnerships**
- **Ethical AI framework**
- **Diverse revenue streams**

## **Growth Strategy**

- **Geographic expansion into EU market (2024)**
- **Launch of SynapseAI™ 2.0 (Q4 2024)**
- **Additional disease indication studies**
- **Strategic partnerships with medical device manufacturers**
- **Expansion into consumer neurotechnology market**

## **Management Team**

- **CEO: Ph.D. in Computational Neuroscience**
- **CTO: Ph.D. in AI and Machine Learning**
- **CSO: Ph.D. in Neurobiology**
- **CMO: MD with 15 years in neurology**
- **CFO: MBA with 20 years in biotech**